Remibrutinib Real-World CSU Study Opens in South Korea
South Korea sub-study of REASSERT will track remibrutinib effectiveness and safety in chronic spontaneous urticaria over 24 months.
Clinical evidence, research, and medical intelligence in Allergy And Immunology.
Clinical evidence, research, and medical intelligence in Allergy And Immunology.